BD Medical Systems: Diabetes Care, Erembodegem, Belgium.
J Diabetes. 2010 Sep;2(3):168-79. doi: 10.1111/j.1753-0407.2010.00077.x.
The efficacy of injection therapy in diabetes depends on correct injection technique and, to provide patients with guidance in this area, we must understand how they currently inject.
From September 2008 to June 2009, 4352 insulin-injecting Type 1 and Type 2 diabetic patients from 171 centers in 16 countries were surveyed regarding their injection practices.
Overall, 3.6% of patients use the 12.7-mm needle, 1.8% use the 12-mm needle, 1.6% use the 10-mm needle, 48.6% use the 8-mm needle, 15.8% use the 6-mm needle, and 21.6% use the 5-mm needle; 7% of patients do not know what length of needle they use. Twenty-one percent of patients admitted injecting into the same site for an entire day, or even a few days, a practice associated with lipohypertrophy. Approximately 50% of patients have or have had symptoms suggestive of lipohypertrophy. Abdominal lipohypertrophy seems to be more frequent in those using the two smaller injection size areas, and less frequent in those using larger areas. Nearly 3% of patients reported always injecting into lipohypertrophic lesions and 26% inject into them sometimes. Of the 65% of patients using cloudy insulins (e.g. NPH), 35% do not remix it before use.
It is clear from the latest survey that we have improved in certain areas, but that, in others, we have either not moved at all or our efforts have not yielded the results we expected. The results of the present survey are available online on a country-by-country and question-by-question basis at http://www.titan-workshop.org.
注射疗法在糖尿病治疗中的疗效取决于正确的注射技术，为了在这方面为患者提供指导，我们必须了解他们目前的注射方式。
2008 年 9 月至 2009 年 6 月，来自 16 个国家 171 个中心的 4352 名 1 型和 2 型胰岛素注射糖尿病患者接受了关于其注射实践的调查。
总体而言，3.6%的患者使用 12.7mm 针头，1.8%使用 12mm 针头，1.6%使用 10mm 针头，48.6%使用 8mm 针头，15.8%使用 6mm 针头，21.6%使用 5mm 针头；7%的患者不知道自己使用的是多长的针头。21%的患者承认在一整天甚至几天内都在同一部位注射，这种做法与脂肪增生有关。大约 50%的患者有或曾经有过脂肪增生的症状。腹部脂肪增生似乎在使用较小注射区域的患者中更为常见，而在使用较大区域的患者中则不太常见。近 3%的患者报告总是在脂肪增生病变部位注射，26%的患者有时会这样做。在使用混浊胰岛素（如 NPH）的 65%的患者中，35%的患者在使用前不混合。
从最新的调查中可以清楚地看出，我们在某些方面有所改善，但在其他方面，我们要么根本没有进展，要么我们的努力没有产生我们预期的结果。本次调查的结果可在 http://www.titan-workshop.org 上按国家和问题逐一查阅。
